Sex differences in glioblastoma response to treatment: Impact of MGMT methylation
Neurooncol Adv
.
2024 Mar 1;6(1):vdae031.
doi: 10.1093/noajnl/vdae031.
eCollection 2024 Jan-Dec.
Authors
Gino Cioffi
1
,
Kristin A Waite
1
,
Mantas Dmukauskas
1
,
Michael Glantz
2
,
Sonikpreet Aulakh
3
,
Theodore Nicolaides
4
,
Soma Sengupta
5
,
Joanne Xiu
4
,
Jill S Barnholtz-Sloan
1
6
Affiliations
1
Trans Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
2
Departments of Neurosurgery and Oncology, Penn State College of Medicine-Hershey Medical Center, Hershey, Pennsylvania, USA.
3
Section of Hematology-Oncology, Department of Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
4
Caris Life Sciences, Phoenix, Arizona, USA.
5
Department of Neurology/Neurosurgery, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
6
Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
PMID:
38476929
PMCID:
PMC10929416
DOI:
10.1093/noajnl/vdae031
No abstract available
Keywords:
MGMT methylation; overall survival; primary brain tumors; sex differences.